The Continued Uptake of Interleukin Inhibitors and TNF-alpha Inhibitors and Increasing Penetration of Biologics Will Drive the Psoriasis Drug Market to Double to $6.8 Billion in 2019

Monday, August 9, 2010 Drug News
Email Print This Page Comment
Font : A-A+

Amgen/GlaxoSmithKline/Pfizer/Takeda's Enbrel Will Face Stiff Competition From Abbott/Eisai's Humira and the Interleukin Inhibitors, According to Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Lisa Osgood

781-296-2606

losgood@hl-isy.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook